Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
ApexOnco Front Page
Recent articles
The company drops the anti-CD19 x 4-1BB project englumafusp alfa.
The company has started a pivotal trial of its KRAS G12D inhibitor in pancreatic cancer.
BeOne's degrader BG-60366 appears to have been discontinued.
The IDO/PD-L1 project mRNA-4359 shows early hints in first-line melanoma.
IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
Daraxonrasib scores a plenary session late-breaker.
The disclosure comes as another of Arcus's TIGIT trials flops.
